Kobayashi Pharmaceutical Co., Ltd. (KBYPF) Stock Analysis

Why this analysis is different

• A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Kobayashi Pharmaceutical Co., Ltd. (KBYPF) Consumer Business Overview

Kobayashi Pharmaceutical Co., Ltd. is a global consumer products company specializing in healthcare, household, skincare, and body warmer products. With a history dating back to 1886, the company offers a diverse portfolio of well-established brands and operates in both domestic and international markets, maintaining a presence in the consumer defensive sector.

What Is the Investment Thesis for KBYPF?

Kobayashi Pharmaceutical Co., Ltd. presents a stable investment opportunity within the consumer defensive sector. The company's diverse product portfolio and established brands provide a degree of resilience against economic downturns. However, a high P/E ratio of 263.74 and a low profit margin of 2.2% raise concerns about valuation and profitability. Growth catalysts include expansion into new international markets and the introduction of innovative products. Potential risks include increasing competition and changing consumer preferences. Investors should carefully consider the company's financial metrics and growth prospects before making an investment decision.

Based on FMP financials and quantitative analysis

KBYPF Key Highlights

Market capitalization of $2.53B indicates a mid-sized company within the consumer defensive sector.

• P/E ratio of 263.74 suggests a high valuation relative to earnings, potentially indicating overvaluation or high growth expectations.
• Gross margin of 51.1% reflects the company's ability to manage production costs and maintain pricing power.
• Dividend yield of 1.85% provides a moderate income stream for investors.
• Beta of 0.32 indicates low volatility compared to the overall market, making it a potentially stable investment.

Who Are KBYPF's Competitors?

KBYPF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are KBYPF's Key Strengths?

Strong brand reputation in Japan and Asia.

• Diverse product portfolio across multiple consumer segments.
• Established distribution network.
• Consistent investment in research and development.

What Are KBYPF's Weaknesses?

High P/E ratio compared to industry peers.

• Low profit margin.
• Limited presence in Western markets.
• Dependence on the Japanese market.

What Could Drive KBYPF Stock Higher?

Potential expansion into new international markets, particularly in Southeast Asia and Latin America.

• Continuous investment in research and development to create innovative products.
• Growing consumer focus on health and wellness trends, driving demand for related products.
• Strategic acquisitions to expand product portfolio and enter new markets.

What Are the Key Risks for KBYPF?

Inconsistent delivery — missed Wall Street EPS estimates in 6 of the last 8 reported quarters.

• Rich valuation — a P/E of 263.74 runs well above the Consumer Defensive sector’s ~27.60x, leaving little room for a miss.
• Increasing competition from multinational corporations in the consumer products industry.
• Changing consumer preferences and trends, requiring continuous adaptation.
• Fluctuations in currency exchange rates, impacting international sales and profitability.
• High P/E ratio compared to industry peers, suggesting potential overvaluation.
• Limited financial disclosure due to OTC listing.

What Are the Growth Opportunities for KBYPF?

• Expansion into Emerging Markets: Kobayashi Pharmaceutical has the opportunity to expand its presence in emerging markets, particularly in Southeast Asia and Latin America. These regions offer significant growth potential due to increasing disposable incomes and a growing demand for consumer products. By adapting its product offerings to local preferences and establishing strategic partnerships, Kobayashi Pharmaceutical can tap into these markets and drive revenue growth. The market size for consumer products in emerging markets is estimated to reach $1.4 trillion by 2028, presenting a substantial opportunity for the company.
• New Product Development: Kobayashi Pharmaceutical can drive growth through continuous innovation and the development of new products that address unmet consumer needs. By investing in research and development, the company can create innovative solutions in areas such as healthcare, skincare, and household products. The launch of new products can attract new customers and increase market share. The global market for new consumer products is estimated at $500 billion annually, providing a significant opportunity for Kobayashi Pharmaceutical to capitalize on innovation.
• Strategic Acquisitions: Kobayashi Pharmaceutical can pursue strategic acquisitions to expand its product portfolio, enter new markets, and gain access to new technologies. By acquiring companies with complementary products or technologies, Kobayashi Pharmaceutical can accelerate its growth and strengthen its competitive position. The company can target acquisitions in areas such as skincare, health supplements, and household cleaning products. The market for mergers and acquisitions in the consumer products industry is active, with deal values reaching $200 billion in 2025.
• E-commerce Expansion: Kobayashi Pharmaceutical can leverage the growth of e-commerce to expand its reach and increase sales. By investing in its online platforms and partnering with e-commerce retailers, the company can reach a wider audience and offer its products directly to consumers. E-commerce provides a cost-effective way to enter new markets and increase brand awareness.
• Focus on Health and Wellness Trends: Kobayashi Pharmaceutical can capitalize on the growing consumer focus on health and wellness by developing and marketing products that promote healthy lifestyles. This includes products such as health supplements, skincare products with natural ingredients, and functional foods. By aligning its product offerings with health and wellness trends, Kobayashi Pharmaceutical can attract health-conscious consumers and drive revenue growth.

What Are KBYPF's Competitive Advantages?

• Strong brand recognition and reputation in Japan and other Asian markets.
• Diverse product portfolio catering to a wide range of consumer needs.
• Established distribution network and relationships with retailers.
• Continuous investment in research and development to create innovative products.

What Does KBYPF Do?

Founded in 1886, Kobayashi Pharmaceutical Co., Ltd. has evolved from a small pharmaceutical manufacturer into a diversified consumer products company. Headquartered in Osaka, Japan, the company's initial focus was on developing and marketing innovative healthcare solutions. Over the years, Kobayashi Pharmaceutical expanded its product lines to include household products, skincare items, and body warmers, catering to a wide range of consumer needs. The company's growth strategy has involved both organic product development and strategic acquisitions, allowing it to build a strong portfolio of well-known brands. Kobayashi Pharmaceutical's product offerings include topical analgesics like Ammeltz, women's health medicines such as Inochi no Haha, and oral hygiene products like BreathCare. The company also provides household cleaning solutions, skincare products, and health supplements. Kobayashi Pharmaceutical distributes its products through various channels, including retail stores, online platforms, and direct sales. With a global presence, the company operates in multiple international markets, adapting its product offerings to meet local consumer preferences and regulatory requirements. Kobayashi Pharmaceutical continues to focus on innovation and quality, aiming to provide consumers with effective and reliable products that enhance their daily lives.

What Products and Services Does KBYPF Offer?

• Manufactures and sells healthcare products, including topical analgesics and women's health medicines.
• Produces and distributes household products such as toilet bowl cleaners and air fresheners.
• Develops and markets skincare products, including medicated lotions and cleansers.
• Offers body warmers for cold weather and therapeutic purposes.
• Manufactures and sells pharmaceuticals and quasi-drugs.
• Markets nutritional supplements and health foods.
• Engages in real estate management and asset management.

How Does KBYPF Make Money?

• Develops, manufactures, and markets a wide range of consumer products.
• Distributes products through retail stores, online platforms, and direct sales channels.
• Generates revenue through the sale of its products to consumers and retailers.
• Invests in research and development to create innovative products.

What Industry Does KBYPF Operate In?

Kobayashi Pharmaceutical Co., Ltd. operates in the competitive household and personal products industry, which is characterized by stable demand and a focus on innovation. The market is driven by consumer spending patterns, demographic trends, and health awareness. Key players in the industry include multinational corporations and regional brands, all vying for market share. Kobayashi Pharmaceutical differentiates itself through its focus on niche product categories and its strong brand reputation in Japan and other Asian markets. The company faces competition from both established players and emerging brands, requiring continuous investment in research and development to maintain its competitive edge.

Who Are KBYPF's Key Customers?

• Consumers seeking healthcare products for pain relief, women's health, and oral hygiene.
• Households looking for cleaning and air freshening solutions.
• Individuals seeking skincare products for acne prevention and general skincare.
• Consumers interested in health supplements and nutritional products.

Company Profile

Kobayashi Pharmaceutical Co., Ltd. operates in the Household & Personal Products industry within the Consumer Defensive sector. It is headquartered in Osaka, JP. The company is led by CEO Norikazu Toyoda. KBYPF has traded publicly since 2015.

Return on equity for Kobayashi Pharmaceutical Co., Ltd. stands at 1.5%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 1.2%, showing how much profit it generates from its asset base. KBYPF trades at a trailing price-to-earnings ratio of 263.74, above the Consumer Defensive sector average of ~27.60x. A current ratio of 3.04 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 0.8%, the inverse of the P/E and a quick read on earnings relative to price.

KBYPF Valuation & Market Position

With a $2.53B market cap, Kobayashi Pharmaceutical Co., Ltd. sits in the mid-cap segment of the market. Relative to its peer group, KBYPF's quantitative score of 50/100 is roughly in line with the peer average of 51/100.

Quarterly Financial Performance: Kobayashi Pharmaceutical Co., Ltd.

Revenue for Kobayashi Pharmaceutical Co., Ltd. came in at $36.82B during Q2 FY2026, a 8.7% improvement versus the preceding quarter. The company recorded net income of $100.3M, with diluted EPS of $1.35. Quarter-over-quarter revenue has been mixed, typical for a mid-cap company operating in Consumer Defensive. Across the four most recent quarters, KBYPF averaged $5.66 in diluted EPS.

Kobayashi Pharmaceutical Co., Ltd.'s Piotroski F-Score is 5/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 7.95 places it in the safe zone, indicating low near-term bankruptcy risk.

Kobayashi Pharmaceutical Co., Ltd. has missed Wall Street's EPS estimate in 6 of its last 8 reported quarters — a mixed record worth weighing. Reported results have landed about 25.2% below estimates on average.

KBYPF Financials

KBYPF Latest News

No recent news available for KBYPF.

KBYPF Analyst Consensus

KBYPF MoonshotScore

Common Questions About KBYPF (Consumer Defensive)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources